Evaluation of pharmacokinetic and pharmacodynamic interactions between escitalopram and drugs used for the treatment of bipolar disorders. - ND

AZIENDA OSPEDALIERA PISANA0 sitesJuly 1, 2008

Overview

No summary available.

Registry

who.int

Start Date

July 1, 2008

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

AZIENDA OSPEDALIERA PISANA

•Male and female patients Age between 18 and 70 years Patients candidate to receive escitalopram for major depressive episodes, depressive episodes, panic, anxiety or obsessive\-compulsive symptoms. Patients treated with: lamotrigine, valproic acid, carbamazepine, oxcarbazepine, gabapentin, levetiracetam, and lithium. Those drugs will be prescribed and administered at doses indicated. Patients with adequate bone marrow, liver and renal function. Patients able to provide a Written Informed Consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range
•F.1\.3 Elderly (\>\=65 years) yes
•F.1\.3\.1 Number of subjects for this age range

•Patients younger than 18 or older than 70 years Patients treated with antipsychotics. Patients need to be treated with antidepressant other than study drug. Patients who will not be able to attend the follow up visits Patients with poor compliance Patients who scored ≥2 at item 3 on HAMD Pregnancy or breast feeding Premenopausal female patients who do not use contraceptives Substance abuse or dependence within the last year A diagnosis of renal or liver failure, jaundice, cardiopathy or severe lung diseases, hematological diseases and past episodes of photosensibilization.